UMN Pharma Inc. reported consolidated and non-consolidated earnings results for the year ended December 31, 2016. For the year, on consolidated basis, net sales were JPY 71 million against JPY 202 million a year ago. Operating loss was JPY 3,564 million against JPY 3,207 million a year ago. Ordinary loss was JPY 3,857 million against JPY 3,390 million a year ago. Net loss was JPY 14,142 million against JPY 3,390 million a year ago. Net loss per share – basic was JPY 1,363.3 against JPY 354.16 a year ago. Cash flows from operating activities were JPY 2,265 million against JPY 3,393 million a year ago. Loss before income tax and minority interests was JPY 14,390.757 million against JPY 3,390.038 million a year ago. Purchase of property, plant and equipment was JPY 1,843.678 million against JPY 407.064 million a year ago. Purchase of intangible assets was JPY 0.459 million against JPY 2.600 million a year ago.

For the year, on non-consolidated basis, net sales were JPY 52 million against JPY 190 million a year ago. Operating loss was JPY 552 million against JPY 709 million a year ago. Ordinary loss was JPY 480 million against JPY 614 million a year ago. Net loss was JPY 8,348 million against JPY 617 million a year ago. Net loss per share – basic was JPY 804.79 against JPY 64.48 a year ago. Cash flows from operating activities were JPY 2,265 million against JPY 3,393 million a year ago.

For the year ending December 31, 2017, the company expects net sales of JPY 153 million, operating loss of JPY 512 million, ordinary loss of JPY 504 million, net loss attributable to owners of parent of JPY 506 million or JPY 41.57 per share.